Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06KXS
|
|||
| Former ID |
DNC012529
|
|||
| Drug Name |
PT-112
|
|||
| Synonyms |
167683-61-6; Thiourea, N-(5-bromo-2-pyridinyl)-N'-(2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl)-; 1-(5-bromopyridin-2-yl)-3-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]thiourea; N-(2-(2-Chloro-3-ethoxy-6-fluorophenethyl))-N'-(2-(5-bromopyridyl))thiourea; PETT deriv. 9; N-[2-(2-Chloro-3-ethoxy-6-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]-; PT-112; AC1MHDLZ; SCHEMBL6906082; CHEMBL398891; BDBM2859; LY300046HCl Analog 10; DTXSID70168348
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H16BrClFN3OS
|
|||
| Canonical SMILES |
CCOC1=C(C(=C(C=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br)Cl
|
|||
| InChI |
1S/C16H16BrClFN3OS/c1-2-23-13-5-4-12(19)11(15(13)18)7-8-20-16(24)22-14-6-3-10(17)9-21-14/h3-6,9H,2,7-8H2,1H3,(H2,20,21,22,24)
|
|||
| InChIKey |
DTHZUSMREBJMBT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 167683-61-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02266745) A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.